Grufity logoGrufity logo

BRKR

68.79USD+0.35(+0.51%)Market Closed

Bruker Corp

Market Summary

USD68.79+0.35Market Closed
0.51%

BRKR Alerts

BRKR Stock Price

RSI Chart

Valuation

Market Cap

9.1B

Price/Earnings

33.17

Price/Sales

3.67

Price/Cashflow

46.38

MarketCap/EBT

23.18

Price/Sales

Profitability

Operating Margin

50.68%

EBT Margin

15.83%

Return on Equity

28.22%

Return on Assets

8.09%

Fundamentals

Revenue

Revenue (TTM)

2.5B

Revenue Y/Y

4.93%

Revenue Q/Q

8.58%

Earnings

Earnings (TTM)

274.9M

Earnings Y/Y

1.15%

Earnings Q/Q

77.98%

Price Action

52 Week Range

48.4287.12
(Low)(High)

Last 7 days

3.9%

Last 30 days

11.6%

Last 90 days

18.5%

Trailing 12 Months

-10.9%

Financial Health

Current Ratio

2.55

Debt/Equity

1.22

Debt/Cashflow

0.17

Investor Care

Dividend Yield

0.3%

Dividend/Share (TTM)

0.2

Buy Backs (1Y)

3.02%

Diluted EPS (TTM)

1.82

Peers (Alternatives to Bruker)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
197.5B
44.2B
9.59% -12.88%
26.51
4.61
13.08% -13.35%
41.1B
6.7B
14.00% 3.09%
30.93
6.17
8.42% 34.14%
36.7B
4.7B
-7.73% -40.09%
-1.9K
7.81
9.79% -558.28%
28.5B
3.9B
14.80% -4.52%
34.68
7.36
7.75% 11.02%
MID-CAP
9.1B
2.5B
11.60% -10.90%
33.17
3.67
6.09% 1.70%
SMALL-CAP
2.0B
137.0M
14.63% -56.78%
-9.53
14.05
12.61% -709.53%
1.1B
159.7M
8.70% -71.21%
-4.68
6.81
19.67% -35.56%
942.2M
496.8M
29.06% -72.73%
-6.42
1.93
2.51% -434.48%
661.5M
23.3M
-12.60% -45.72%
-6.25
28.36
76.56% -106.44%
413.2M
110.0M
8.29% -73.27%
-5.25
3.72
3.37% -106.72%
372.0M
132.7M
-6.72% -85.20%
-19.64
2.76
31.03% -107.73%
187.1M
42.4M
-42.36% -80.13%
-2.44
4.51
30.40% -43.67%
109.5M
118.0M
- -66.15%
-29.97
0.91
0.97% -269.58%
105.9M
68.8M
15.65% -66.00%
-3.75
1.53
5.65% 26.86%

Financials for Bruker

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Revenue1.2%2,5062,4762,4582,4182,362
Cost Of Revenue0.3%1,2241,2211,2211,2081,181
Gross Profit2.1%1,2811,2551,2371,2101,181
Operating Expenses1.0%854846817796780
  S&GA Expenses0.6%596593575561538
  R&D Expenses1.8%231226223221220
Earnings Before Taxes5.2%412392402394380
Net Income0.4%275274282277270
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets-1.4%3,3373,3853,5513,6503,128
  Current Assets-2.4%2,0372,0882,2512,4721,989
    Cash Equivalents-13.4%6267238161,068573
  Inventory-1.3%750759740710733
  Net PPE6.7%422395404406389
  Goodwill-3.7%382396384340324
  Current Liabilities5.6%865818881939921
  Long Term Debt-2.6%1,1541,1851,2161,334827
    LT Debt, Non Current-2.9%1,1371,1711,2051,222718
Shareholder's Equity-3.5%9379711,0171,0711,076
  Retained Earnings-1,660----
  Additional Paid-In Capital-238----
Shares Outstanding-0.6%147148149151152
Minority Interest-20.9%1114141414
* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations23.3%242196262282347
  Share Based Compensation0.5%2121211716
Cashflow From Investing-6.5%-150.90-141.70-270.20-192.40-172.60
Cashflow From Financing-76.0%25105139319-159.90
  Dividend Payments4.8%2827262424
  Buy Backs29.2%321248226153140

Risks

What is the probability of a big loss on BRKR?

56.1%


Probability that Bruker stock will be more than 20% underwater in next one year

33.1%


Probability that Bruker stock will be more than 30% underwater in next one year.

3.9%


Probability that Bruker stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does BRKR drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Bruker was unfortunately bought at previous high price.

Returns

Cumulative Returns on BRKR

17.1%


10-Year Cumulative Returns

17.7%


7-Year Cumulative Returns

14.6%


5-Year Cumulative Returns

10.9%


3-Year Cumulative Returns

What are the long-term rolling returns for BRKR?

FIve years rolling returns for Bruker.

Which funds bought or sold BRKR recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-22
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
NEW
-
844,000
844,000
0.01%
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
REDUCED
-2.67
-1,521,000
7,064,000
0.01%
2022-11-16
Retirement Systems of Alabama
ADDED
0.11
-1,271,000
6,997,000
0.03%
2022-11-16
Neo Ivy Capital Management
NEW
-
57,000
57,000
0.15%
2022-11-16
Front Row Advisors LLC
NEW
-
6,000
6,000
-%
2022-11-16
CAPTRUST FINANCIAL ADVISORS
ADDED
199
183,000
302,000
-%
2022-11-16
Advisors Capital Management, LLC
ADDED
6.57
4,388,000
28,973,000
0.77%
2022-11-15
BNP PARIBAS ARBITRAGE, SNC
REDUCED
-31.68
-1,933,720
2,643,930
-%
2022-11-15
IMA Wealth, Inc.
NEW
-
-
-
-%
2022-11-15
UNITED SERVICES AUTOMOBILE ASSOCIATION
UNCHANGED
-
-106,000
577,000
0.02%

1–10 of 45

Latest Funds Activity

Are funds buying BRKR calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own BRKR

Bruker News

ETF Daily News

Bank of Montreal Can Sells 4735 Shares of Bruker Co. (NASDAQ:BRKR).45 hours ago

Yahoo Finance

BRKR Fair Value

Recent SEC filings of Bruker

View All Filings
Date Filed Form Type Document
Nov 17, 2022
4
Insider Trading
Nov 04, 2022
10-Q
Quarterly Report
Nov 03, 2022
8-K
Current Report

Latest Insider Trading transactions for BRKR

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-11-15
Kastner Marc A
SOLD
-707,490
70.749
-10,000
-
2022-11-15
Kastner Marc A
ACQUIRED
240,000
24
10,000
-
2022-08-11
Munch Mark
ACQUIRED
-
-
12,770
EXEC VP&PRES BRUKER NANO INC.
2022-08-11
Prause Burkhard
ACQUIRED
-
-
2,440
PRES. & CEO, BRUKER BEST
2022-08-11
Busse Falko
ACQUIRED
-
-
4,658
PRESIDENT, BIOSPIN GROUP
2022-08-11
LAUKIEN FRANK H
ACQUIRED
-
-
40,023
PRESIDENT & CEO
2022-08-11
Herman Gerald N
ACQUIRED
-
-
12,521
EXECUTIVE VICE PRESIDENT, CFO
2022-08-09
LAUKIEN FRANK H
SOLD (Taxes)
-363,186
60.34
-6,019
PRESIDENT & CEO
2022-08-09
Munch Mark
SOLD (Taxes)
-151,755
60.34
-2,515
EXEC VP&PRES BRUKER NANO INC.
2022-08-08
Munch Mark
SOLD (Taxes)
-133,085
62.16
-2,141
EXEC VP&PRES BRUKER NANO INC.

1–10 of 50

Frank H. Laukien
7760
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation has a collaboration with Newomics Inc. on a LC-MS platform for drug discovery. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.

BRKR Income Statement

2022-09-30
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME - USD ($)
$ in Millions
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Total revenue$ 638.9$ 608.9$ 1,822.3$ 1,734.4
Total cost of revenue303.6300.2882.5866.4
Gross profit335.3308.7939.8868.0
Operating expenses:    
Selling, general and administrative144.8141.3442.7407.9
Research and development56.252.1172.4162.7
Other charges, net3.02.123.09.5
Total operating expenses204.0195.5638.1580.1
Operating income131.3113.2301.7287.9
Interest and other income (expense), net(2.0)(4.4)(8.8)(13.8)
Income before income taxes, equity in income of unconsolidated investee, net of tax, and noncontrolling interests in consolidated subsidiaries129.3108.8292.9274.1
Income tax provision41.220.793.069.5
Equity in income of unconsolidated investee, net of tax0.30.00.30.0
Consolidated net income88.488.1200.2204.6
Net income attributable to noncontrolling interests in consolidated subsidiaries0.31.01.03.2
Net income attributable to Bruker Corporation$ 88.1$ 87.1$ 199.2$ 201.4
Net income per common share attributable to Bruker Corporation shareholders:    
Basic$ 0.60$ 0.58$ 1.34$ 1.33
Diluted$ 0.59$ 0.57$ 1.33$ 1.32
Weighted average common shares outstanding:    
Basic (in shares)147.8151.4149.1151.5
Diluted (in shares)148.6152.8149.9153.0
Comprehensive income$ 44.6$ 73.1$ 113.7$ 188.1
Less: Comprehensive (loss) income attributable to noncontrolling interests(0.3)0.7(0.5)0.9
Less: Comprehensive loss attributable to redeemable noncontrolling interest(0.6)0.0(1.3)0.0
Comprehensive income attributable to Bruker Corporation45.572.4115.5187.2
Product    
Total revenue536.6508.31,512.81,441.2
Total cost of revenue240.5243.5699.6700.4
Service    
Total revenue100.999.0305.0287.8
Total cost of revenue63.156.5182.8165.3
Other    
Total revenue1.41.64.55.4
Total cost of revenue$ 0.0$ 0.2$ 0.1$ 0.7

BRKR Balance Sheet

2022-09-30
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 626.2$ 1,068.2
Short-term investments0.0100.0
Accounts receivable, net421.3416.9
Inventories749.5710.1
Assets held for sale0.04.4
Other current assets239.6172.2
Total current assets2,036.62,471.8
Property, plant and equipment, net421.5406.1
Goodwill381.5339.5
Intangible assets, net214.0211.8
Other long-term assets283.3220.8
Total assets3,336.93,650.0
Current liabilities:  
Current portion of long-term debt17.0112.4
Accounts payable157.7147.4
Customer advances175.5197.5
Other current liabilities514.4481.2
Total current liabilities864.6938.5
Long-term debt1,136.81,221.8
Other long-term liabilities381.8404.9
Commitments and contingencies (Note 14)
Redeemable noncontrolling interests5.70.2
Shareholders' equity:  
Preferred stock, $0.01 par value 5,000,000 shares authorized, none issued or outstanding0.00.0
Common stock, $0.01 par value 260,000,000 shares authorized, 175,297,676 and 174,905,035 shares issued and 147,366,634 and 150,753,687 shares outstanding at September 30, 2022 and December 31, 2021, respectively1.71.7
Treasury stock, at cost, 27,931,042 and 24,151,348 shares at September 30, 2022 and December 31, 2021, respectively(1,058.6)(820.3)
Accumulated other comprehensive loss, net of tax(92.1)(8.2)
Other shareholders' equity2,086.01,897.3
Total shareholders' equity attributable to Bruker Corporation937.01,070.5
Noncontrolling interests in consolidated subsidiaries11.014.1
Total shareholders' equity948.01,084.6
Total liabilities, redeemable noncontrolling interests and shareholders' equity$ 3,336.9$ 3,650.0